Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$733.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $718.00 1
Food and Beverage $15.57 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $718.00 1
Teva Pharmaceuticals USA, Inc. $15.57 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1659322691?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $733.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $718.0012/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737274507 CMS
Teva Pharmaceuticals USA, Inc. $15.5701/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749461225 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

166 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $112.05 12/22/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896849891
Principal investigator 1 Novo Nordisk AS $51.95 12/22/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896907245
Principal investigator 1 Novo Nordisk AS $1,286.82 12/21/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896879759
Principal investigator 1 ABBVIE INC. $9,500.00 12/07/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimerx27s Disease No dispute reported 06/30/2026 890368655
Principal investigator 1 Novo Nordisk AS $6.50 12/01/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896893427
Principal investigator 1 Novo Nordisk AS $5.05 12/01/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896900939
Principal investigator 1 Genentech, Inc. $17,999.00 11/28/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 950638625
Principal investigator 1 Novo Nordisk AS $14,902.56 11/23/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896893423
Principal investigator 1 Eisai Inc. $13,481.10 11/22/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006185
Principal investigator 1 Genentech, Inc. $5,655.00 11/14/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 950639443
Principal investigator 1 Novo Nordisk AS $1,441.80 10/21/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896880197
Principal investigator 1 Eisai Inc. $49,401.00 10/19/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006181
Principal investigator 1 Eisai Inc. $61,168.50 10/19/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006183
Principal investigator 1 Novo Nordisk AS $3,356.64 09/30/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896907249
Principal investigator 1 Eisai Inc. $24,147.00 09/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006177
Principal investigator 1 Eisai Inc. $14,890.50 09/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006179
Principal investigator 1 Eli Lilly and Company $495.00 09/21/2022 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917822295
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006047
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006049
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006051
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006053
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006055
Principal investigator 1 Eisai Inc. $1,591.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006057
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006059
Principal investigator 1 Eisai Inc. $2,967.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006061
Principal investigator 1 Eisai Inc. $2,904.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006063
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006065
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006067
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006069
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006071
Principal investigator 1 Eisai Inc. $1,481.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006073
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006075
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006077
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006079
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006081
Principal investigator 1 Eisai Inc. $2,967.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006083
Principal investigator 1 Eisai Inc. $2,904.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006085
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006087
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006089
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006091
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006093
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006095
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006097
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006099
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006101
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006103
Principal investigator 1 Eisai Inc. $2,967.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006105
Principal investigator 1 Eisai Inc. $2,904.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006107
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006109
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006111
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006113
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006115
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006117
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006119
Principal investigator 1 Eisai Inc. $2,967.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006121
Principal investigator 1 Eisai Inc. $2,904.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006123
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006125
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006127
Principal investigator 1 Eisai Inc. $632.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006129
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006131
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006133
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006135
Principal investigator 1 Eisai Inc. $1,442.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006137
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006139
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006141
Principal investigator 1 Eisai Inc. $1,387.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006143
Principal investigator 1 Eisai Inc. $2,967.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006145
Principal investigator 1 Eisai Inc. $2,904.00 09/16/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006147
Principal investigator 1 Novo Nordisk AS $35.00 09/16/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896951659
Principal investigator 1 Biogen, Inc. $28,594.20 09/06/2022 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 927058789
Principal investigator 1 Genentech, Inc. $1,880.00 08/25/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 950651381
Principal investigator 1 Eisai Inc. $43,356.60 08/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006175
Principal investigator 1 Genentech, Inc. $26,100.00 08/17/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 950653165
Principal investigator 1 Novo Nordisk AS $19,082.34 07/27/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896969843
Principal investigator 1 Eli Lilly and Company $5,684.00 07/26/2022 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917821249
Principal investigator 1 Eisai Inc. $7,855.20 07/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006171
Principal investigator 1 Eisai Inc. $21,279.60 07/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006173
Principal investigator 1 Novo Nordisk AS $2,847.24 06/29/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896858167
Principal investigator 1 Biogen, Inc. $8,971.00 06/22/2022 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Prospective Real-World Observational Study Of Aducanumab In Patients With Alzheimers Disease: ICARE AD US No dispute reported 06/30/2026 927059551
Principal investigator 1 Eisai Inc. $12,211.20 06/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006167
Principal investigator 1 Eisai Inc. $51,678.00 06/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006169
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006021
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006023
Principal investigator 1 Eisai Inc. $1,481.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006025
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006027
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006029
Principal investigator 1 Eisai Inc. $1,481.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006031
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006033
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006035
Principal investigator 1 Eisai Inc. $1,442.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006037
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006039
Principal investigator 1 Eisai Inc. $1,442.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006041
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006043
Principal investigator 1 Eisai Inc. $1,387.00 06/10/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006045
Principal investigator 1 Eli Lilly and Company $14,547.00 05/26/2022 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 917821251
Principal investigator 1 Eisai Inc. $17,334.90 05/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006165
Principal investigator 1 Genentech, Inc. $8,971.00 05/20/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 950668975
Principal investigator 1 Genentech, Inc. $36,067.00 05/20/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 950669353
Principal investigator 1 Genentech, Inc. $6,279.00 05/11/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 950671169
Recipient Eli Lilly and Company $250.00 04/29/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917807813
Principal investigator 1 Novo Nordisk AS $1,881.36 04/29/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896976783
Principal investigator 1 Eisai Inc. $116,334.90 04/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006161
Principal investigator 1 Eisai Inc. $67,711.50 04/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006163
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005925
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005927
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005929
Principal investigator 1 Eisai Inc. $2,967.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005931
Principal investigator 1 Eisai Inc. $2,904.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005933
Principal investigator 1 Eisai Inc. $1,537.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005935
Principal investigator 1 Eisai Inc. $1,632.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005937
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005939
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005941
Principal investigator 1 Eisai Inc. $1,576.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005943
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005945
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005947
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005949
Principal investigator 1 Eisai Inc. $2,967.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005951
Principal investigator 1 Eisai Inc. $2,904.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005953
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005955
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005957
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005959
Principal investigator 1 Eisai Inc. $1,442.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005961
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005963
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005965
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005967
Principal investigator 1 Eisai Inc. $1,576.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005969
Principal investigator 1 Eisai Inc. $2,957.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005971
Principal investigator 1 Eisai Inc. $2,904.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005973
Principal investigator 1 Eisai Inc. $4,078.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005975
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005977
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005979
Principal investigator 1 Eisai Inc. $1,442.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005981
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005983
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005985
Principal investigator 1 Eisai Inc. $1,481.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005987
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005989
Principal investigator 1 Eisai Inc. $1,498.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005991
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005993
Principal investigator 1 Eisai Inc. $1,442.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005995
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005997
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926005999
Principal investigator 1 Eisai Inc. $1,738.10 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006001
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006003
Principal investigator 1 Eisai Inc. $1,442.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006005
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006007
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006009
Principal investigator 1 Eisai Inc. $2,904.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006011
Principal investigator 1 Eisai Inc. $1,387.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006013
Principal investigator 1 Eisai Inc. $1,836.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006015
Principal investigator 1 Eisai Inc. $2,904.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006017
Principal investigator 1 Eisai Inc. $4,078.00 03/23/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006019
Principal investigator 1 Eisai Inc. $4,957.20 03/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006157
Principal investigator 1 Eisai Inc. $15,875.10 03/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006159
Principal investigator 1 Novo Nordisk AS $1,466.82 02/25/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896906973
Principal investigator 1 Genentech, Inc. $14,312.00 02/22/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
POSTGRADUATE ROLL OVER STUDY No dispute reported 06/30/2026 950683955
Principal investigator 1 Genentech, Inc. $2,820.00 02/22/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB OPEN LABEL EXTENSION No dispute reported 06/30/2026 950684225
Principal investigator 1 Genentech, Inc. $3,000.00 02/22/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
HCRU AMONG MEDICARE ENROLLED PTS PARTICIPATING IN SPONSOR CONDUCTED PHASE III CLINICAL TRIALS IN AD No dispute reported 06/30/2026 950748485
Principal investigator 1 Eisai Inc. $7,855.20 02/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006153
Principal investigator 1 Eisai Inc. $35,099.10 02/21/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006155
Principal investigator 1 Genentech, Inc. $9,690.00 02/14/2022 Non-covered Recipient Entity
AMC RESEARCH LLC
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 950684539
Principal investigator 1 Novo Nordisk AS $7,152.30 02/07/2022 Non-covered Recipient Entity
AMC RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 896960129
Principal investigator 1 Biogen, Inc. $304,447.00 01/26/2022 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 927058787
Principal investigator 1 Eisai Inc. $10,800.90 01/25/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006149
Principal investigator 1 Eisai Inc. $30,379.50 01/20/2022 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926006151
Principal investigator 1 Eli Lilly and Company $13,185.00 01/20/2022 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820467
Principal investigator 1 Eli Lilly and Company $1,083,106.00 01/04/2022 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917820951